N-(3-bromo-2-methylphenyl)-2-(pyridin-2-yl)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-bromo-2-methylphenyl)-2-(pyridin-2-yl)acetamide
• 英文别名: N-(3-bromo-2-methylphenyl)-2-pyridin-2-ylacetamide
• 化学式: C₁₄H₁₃BrN₂O
• 分子量: 305.174
• InChiKey: PHXASFSAJUNCJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-bromo-2-methylphenyl)-2-(pyridin-2-yl)acetamide 在 Selectfluor 作用下， 以 1,2-二氯乙烷 为溶剂， 以33%的产率得到N-(3-bromo-2-methylphenyl)-2-fluoro-2-(pyridin-2-yl)acetamide
  参考文献：
  名称：

  [EN] CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS
  [FR] COMPOSÉS DE CARBAZOLE-CARBOXAMIDE UTILES COMME INHIBITEURS DE KINASES

  摘要：

  公开了Formula (I)的化合物及其盐，其中：Formula (II)；Q是：R1为-C(CH3)2OH，-NHC(=0)C(CH3)3，-N(CH3)2，或-CH2Rd；R2为CI或-CH3；R3为H，F或-CH3；Ra为H或-CH3；Rb为H，F，CI或-OCH3；Rc为H或F；Rd为-OH，-OCH3，-NHC(=0)CH3，或Formula (III)。还公开了使用这些化合物作为Bruton酪氨酸激酶（Btk）抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓各种治疗领域的疾病或障碍方面具有用途，如自身免疫疾病和血管疾病。

  公开号：

  WO2014210087A1
• 作为产物：
  描述：

  2-吡啶乙酸乙酯 在 水 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-(3-bromo-2-methylphenyl)-2-(pyridin-2-yl)acetamide
  参考文献：
  名称：

  Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK

  摘要：

  Bruton's tyrosine kinase (BTK) has been shown to play a key role in the pathogenesis of autoimmunity. Therefor; the inhibition of the kinase activity of BTK with a small molecule inhibitor could offer a breakthrough in the clinical treatment of many autoimmune diseases. This Letter describes the discovery of BMS-986143 through systematic structure-activity relationship (SAR) development. This compound benefits from defined chirality derived from two rotationally stable atropisomeric axes, providing a potent and selective single atropisomer with desirable efficacy and tolerability profiles.

  DOI：

  10.1021/acsmedchemlett.0c00335

文献信息

• CARBAZOLE CARBOXAMIDE COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160200710A1

  公开（公告）日：2016-07-14

  Disclosed are compounds of Formula (I); and salts thereof, wherein: Formula (II); Q is: R 1 is —C(CH 3 )2OH, —NHC(=0)C(CH 3 ) 3 , —N(CH3)2, or —CH 2 R d ; R 2 is CI or —CH 3 ; R 3 is H, F, or —CH 3 ; R a is H or —CH 3 ; R b is H, F, CI, or —OCH3 R c is H or F; and Rd is —OH, —OCH3, —NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）化合物及其盐，其中：式（II）；Q为：R1为—C（CH3）2OH，—NHC（=0）C（CH3）3，—N（CH3）2或—CH2Rd；R2为CI或—CH3；R3为H，F或—CH3；Ra为H或—CH3；Rb为H，F，CI或—OCH3；Rc为H或F；Rd为—OH，—OCH3，—NHC（=0）CH3或式（III），还公开了使用这些化合物作为Bruton酪氨酸激酶（Btk）抑制剂的方法以及包含这些化合物的制药组合物。这些化合物在多种治疗领域中，如自身免疫疾病和血管疾病中，用于治疗、预防或减缓疾病或疾病的进展。
• CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3013815B1

  公开（公告）日：2017-05-03
• US9714234B2
  申请人：——

  公开号：US9714234B2

  公开（公告）日：2017-07-25
• [EN] CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS DE CARBAZOLE-CARBOXAMIDE UTILES COMME INHIBITEURS DE KINASES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014210087A1

  公开（公告）日：2014-12-31

  Disclosed are compounds of Formula (I); and salts thereof, wherein:Formula (II); Q is: R1 is -C(CH3)2OH, -NHC(=0)C(CH3)3, -N(CH3)2, or -CH2Rd; R2 is CI or -CH3; R3 is H, F, or -CH3; Ra is H or -CH3; Rb is H, F, CI, or -OCH3 Rc is H or F; and Rd is -OH, -OCH3, -NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  公开了Formula (I)的化合物及其盐，其中：Formula (II)；Q是：R1为-C(CH3)2OH，-NHC(=0)C(CH3)3，-N(CH3)2，或-CH2Rd；R2为CI或-CH3；R3为H，F或-CH3；Ra为H或-CH3；Rb为H，F，CI或-OCH3；Rc为H或F；Rd为-OH，-OCH3，-NHC(=0)CH3，或Formula (III)。还公开了使用这些化合物作为Bruton酪氨酸激酶（Btk）抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓各种治疗领域的疾病或障碍方面具有用途，如自身免疫疾病和血管疾病。
• Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK
  作者：Anurag S. Srivastava、Soo Ko、Scott H. Watterson、Mark A. Pattoli、Stacey Skala、Lihong Cheng、Mary T. Obermeier、Rodney Vickery、Lorell N. Discenza、Celia J. D’Arienzo、Kathleen M. Gillooly、Tracy L. Taylor、Claudine Pulicicchio、Kim W. McIntyre、Shiuhang Yip、Peng Li、Dawn Sun、Dauh-Rurng Wu、Jun Dai、Chunlei Wang、Yingru Zhang、Bei Wang、Joseph Pawluczyk、James Kempson、Rulin Zhao、Xiaoping Hou、Richard Rampulla、Arvind Mathur、Michael A. Galella、Luisa Salter-Cid、Joel C. Barrish、Percy H. Carter、Aberra Fura、James R. Burke、Joseph A. Tino

  DOI：10.1021/acsmedchemlett.0c00335

  日期：2020.11.12

  Bruton's tyrosine kinase (BTK) has been shown to play a key role in the pathogenesis of autoimmunity. Therefor; the inhibition of the kinase activity of BTK with a small molecule inhibitor could offer a breakthrough in the clinical treatment of many autoimmune diseases. This Letter describes the discovery of BMS-986143 through systematic structure-activity relationship (SAR) development. This compound benefits from defined chirality derived from two rotationally stable atropisomeric axes, providing a potent and selective single atropisomer with desirable efficacy and tolerability profiles.